Revolution Medicines (RVMD) Stock Up Nearly 140% in 2026

Revolution Medicines (RVMD) has seen its stock price soar nearly 140% in 2026. This increase is attributed to positive late-stage clinical trial results, including a phase 3 trial for daraxonrasib in metastatic pancreatic cancer, which demonstrated a survival rate of 13.2 months versus the standard care's 6.7 months. The company is advancing additional candidates, including zoldonrasib, also in phase 3 trials, signaling potential revenue growth ahead. These developments are significant as they may impact investor sentiment and the biotechnology sector.